News Releases

May 25, 2021
LAVA Therapeutics to Present at 2021 Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 25, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive
» Full Release
May 20, 2021
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results
IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023 Clinical development plans on schedule in both hematological and solid tumor programs Leadership strengthened through key management and board appointments
» Full Release
May 18, 2021
LAVA Therapeutics to Present at 2021 UBS Global Healthcare Virtual Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 18, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive
» Full Release
April 1, 2021
LAVA Therapeutics Appoints Karen J. Wilson to its Board of Directors
UTRECHT, The Netherlands and PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCEs) to transform cancer therapy, today announced that Karen J.
» Full Release
March 24, 2021
LAVA Therapeutics Announces Pricing of Initial Public Offering
UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics B.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the pricing of its initial public
» Full Release
March 15, 2021
LAVA Therapeutics B.V. Appoints Edward F. Smith as Chief Financial Officer
Veteran biopharma CFO brings over 20 years of experience leading finance functions at publicly traded pharmaceutical companies Utrecht, The Netherlands and Philadelphia, USA – March 15, 2021 – LAVA Therapeutics B.V. (“LAVA”, or the “Company”), a biotechnology company focused on applying its
» Full Release
March 10, 2021
LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
Utrecht, The Netherlands and Philadelphia, USA – March 10, 2021 – LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bs TCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate
» Full Release
February 22, 2021
LAVA Therapeutics Appoints Dr. Kapil Dhingra as Chairman of the Board of Directors in Advance of Lead Program Entering the Clinic
Utrecht, The Netherlands and Philadelphia, USA – February 22, 2021 – LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr.
» Full Release
January 5, 2021
LAVA Therapeutics to Present Corporate Overview at 39th Annual J.P. Morgan Healthcare Conference
Utrecht, The Netherlands and Philadelphia, USA  – January 5, 2021 – LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in gamma-delta T-cell engagers to transform cancer therapy, today announced that Stephen Hurly, chief executive officer, will present a corporate
» Full Release